Welcome to our dedicated page for Cartesian Therapeutics news (Ticker: RNAC), a resource for investors and traders seeking the latest updates and insights on Cartesian Therapeutics stock.
Cartesian Therapeutics, Inc. reports news on its late clinical-stage biotechnology work in mRNA-engineered cell therapy for autoimmune diseases. The company's lead asset, Descartes-08, is an autologous BCMA-targeting CAR-T candidate being developed for generalized myasthenia gravis, myositis indications such as dermatomyositis and antisynthetase syndrome, and pediatric autoimmune diseases including juvenile dermatomyositis.
Recurring updates cover clinical program progress across AURORA, TRITON and HELIOS, FDA designations for Descartes-08, financial results and cash runway commentary, corporate presentations and investor conference participation. News also includes Nasdaq employment inducement grants, equity incentive plan activity, and board or committee changes tied to the company's public-company governance.
Cartesian Therapeutics (NASDAQ: RNAC) announced inducement stock-option awards to two new employees dated Oct 27, 2025 and Oct 29, 2025. One option covers 50,000 shares at an exercise price of $8.85 (closing price on Oct 27, 2025); the other covers 2,650 shares at an exercise price of $8.20 (closing price on Oct 29, 2025).
Both grants were approved by the board under the Amended and Restated 2018 Employment Inducement Incentive Award Plan, vest 25% after one year then in three equal annual installments (fully vested in 2029), and carry a 10-year term. Grants were made under Nasdaq Rule 5635(c)(4) as inducements to employment.
Cartesian Therapeutics (NASDAQ: RNAC) announced that Carsten Brunn, Ph.D., currently President and CEO, was named Chairman of the Board effective October 29, 2025.
Dr. Brunn succeeds Carrie S. Cox, who is stepping down to focus on other responsibilities, including a recent appointment as Executive Chair of another publicly traded company. In connection with the change, Patrick Zenner, M.B.A. was named Lead Independent Director.
The company highlighted progress advancing Descartes-08 toward its first planned regulatory submission and referenced the board leadership transition as part of its corporate governance updates.
Cartesian Therapeutics (NASDAQ: RNAC) announced an employment inducement grant for one new employee on Oct 2, 2025. The company issued an option for 9,700 shares with an exercise price of $10.34 (Nasdaq close on grant date). The option was approved by the board and granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement award.
The option vests 25% on Oct 2, 2026, then in three equal annual installments, becoming fully vested on Oct 2, 2029, and carries a 10-year term.
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on cell therapy for autoimmune diseases, has announced its participation in three major healthcare investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference on September 4, the Morgan Stanley Healthcare Conference on September 9, and the H.C. Wainwright Global Investment Conference on September 10. All presentations will be available via webcast on the company's website.
Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 2025 financial results and provided key pipeline updates. The company has initiated its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis, with the first participant enrolled in May 2025. The trial will evaluate the therapy versus placebo in approximately 100 participants.
The company maintains a strong financial position with $162.1 million in cash and equivalents as of June 30, 2025, expected to fund operations into mid-2027. Q2 2025 saw a net income of $15.9 million ($0.51 per share). Cartesian anticipates preliminary data from its Phase 2 trial of Descartes-08 in systemic lupus erythematosus and plans to initiate a pediatric basket trial in select autoimmune indications in 2H25.
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, has granted employment inducement awards to two new employees. The company issued stock options to purchase 5,750 shares at an exercise price of $12.48 per share on August 4, 2025.
The options were granted under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan with a four-year vesting schedule. The initial 25% vests on August 4, 2026, followed by three equal annual installments, becoming fully vested by August 4, 2029. The options have a ten-year term and were granted under Nasdaq Rule 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC) reported its Q1 2025 financial results and provided significant pipeline updates. The company's lead candidate Descartes-08 showed promising Phase 2b results in myasthenia gravis (MG), with sustained benefits through 12 months after a single course of therapy. Notably, patients without prior biologic exposure showed an average 7.1-point reduction in MG-ADL, with 57% maintaining minimum symptoms at Month 12.
The company plans to initiate the Phase 3 AURORA trial for Descartes-08 in MG in Q2 2025. Additional milestones expected in H2 2025 include preliminary data from a Phase 2 trial in systemic lupus erythematosus and initiation of a pediatric basket trial. Financially, Cartesian reported $182.1 million in cash and equivalents as of March 31, 2025, expected to fund operations into mid-2027. Q1 2025 net loss was $(17.7) million, or $(0.68) per share.